Norway Precision Medicine Market Size & Outlook, 2026-2033
Global Market
Related Markets
Norway precision medicine market highlights
- The Norway precision medicine market generated a revenue of USD 765.8 million in 2025 and is expected to reach USD 1,842.2 million by 2033.
- The Norway market is expected to grow at a CAGR of 11.7% from 2026 to 2033.
- In terms of segment, therapeutics was the largest revenue generating application in 2025.
- Diagnostics is the most lucrative application segment registering the fastest growth during the forecast period.
Precision medicine market data book summary
| Market revenue in 2025 | USD 765.8 million |
| Market revenue in 2033 | USD 1,842.2 million |
| Growth rate | 11.7% (CAGR from 2026 to 2033) |
| Largest segment | Therapeutics |
| Fastest growing segment | Diagnostics |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, Norway accounted for 0.7% of the global precision medicine market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany precision medicine market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 15,236.5 million by 2033.
In December 2021, Illumina, Inc. announced that it would be supporting Norway’s precision medicine study to evaluate blood-based Comprehensive Genomic Profiling (CGP) efficiency in the selection of cancer therapy. The study would also evaluate the cost-effectiveness of blood-based CGP implementation in the healthcare system.
Tissue sampling could be replaced with less invasive CGP testing on blood samples, thus expanding the number of people whose tumors can be profiled and who can then be enrolled in clinical trials for cancer therapy selection. Norway has established a network of drug information centers, Regionale legemiddelinformasjonssentre (RELIS).
This service promotes access to personalized medicine in the country. In October 2020, the government of Norway increased the budget for personalized medicine in its newly released state budget. The budget was increased to a total of USD 5.69 million (NOK 61.3 million). This increased budget is intended to be used to improve molecular diagnostics capabilities in hospitals to increase the adoption of precision medicine.
No credit card required*
Publish Date: May 12, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Precision Medicine Diagnostics Therapeutics Market
Precision Medicine Diagnostics Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| GE HealthCare Technologies Inc Common Stock | View profile | 51,000 | 500 West Monroe Street, Chicago, IL, United States, 60661 | www.gehealthcare.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| International Business Machines Corp | View profile | 282,200 | One New Orchard Road, Armonk, NY, United States, 10504 | www.ibm.com |
| Medtronic PLC | View profile | 95,000 | Lower Hatch Street, 20 On Hatch, Dublin, Ireland, 2 | www.medtronic.com |
| Siemens Healthineers AG ADR | View profile | 71,400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | www.siemens-healthineers.com |
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Myriad Genetics Inc | View profile | 2,700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | www.myriad.com |
| Dakota Software | View profile | 51-100 | Cleveland, Ohio, United States, North America | dakotasoft.com |
Norway precision medicine diagnostics therapeutics market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Precision Medicine Market Outlook will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 89.66% in 2025.
Horizon Databook has segmented the Norway precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.
In December 2021, Illumina, Inc. announced that it would be supporting Norway’s precision medicine study to evaluate blood-based Comprehensive Genomic Profiling (CGP) efficiency in the selection of cancer therapy. The study would also evaluate the cost-effectiveness of blood-based CGP implementation in the healthcare system.
Tissue sampling could be replaced with less invasive CGP testing on blood samples, thus expanding the number of people whose tumors can be profiled and who can then be enrolled in clinical trials for cancer therapy selection. Norway has established a network of drug information centers, Regionale legemiddelinformasjonssentre (RELIS).
This service promotes access to personalized medicine in the country. In October 2020, the government of Norway increased the budget for personalized medicine in its newly released state budget. The budget was increased to a total of USD 5.69 million (NOK 61.3 million). This increased budget is intended to be used to improve molecular diagnostics capabilities in hospitals to increase the adoption of precision medicine.
- Norway Precision Medicine Market Application Outlook (Revenue, USD Million , 2021-2033)
- Diagnostics
- Therapeutics
- Norway Precision Medicine Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Home Care
- Hospitals
- Clinical Laboratories
- Others
Reasons to subscribe to precision medicine diagnostics therapeutics market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of precision medicine diagnostics therapeutics market databook
- Our clientele includes a mix of precision medicine diagnostics therapeutics market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway precision medicine diagnostics therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Norway precision medicine diagnostics therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Norway Precision Medicine Market, 2021-2033 (US$M)
Norway Application - Precision Medicine Market Statistics, 2025 - 2033 (US$M)
